Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2018

Study Completion Date

October 31, 2018

Conditions
Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Interventions
DRUG

Intravitreal bevacizumab

A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.

PROCEDURE

Small-gauge pars plana vitrectomy

Trial Locations (1)

11462

King Khaled Eye Specialist Hospital, Riyadh

All Listed Sponsors
collaborator

Pan American Collaborative Retina Study Group

NETWORK

lead

J. Fernando Arevalo, MD FACS

OTHER_GOV

NCT01976923 - Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter